KTRA

KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRA

Retrieved on: 
Friday, April 5, 2024
Class Action Lawsuit, Professional Services, Legal, KSF, KTRA, Therapy

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kintara Therapeutics, Inc. (the “Company”) (NasdaqCM: KTRA) and TuHURA Biosciences, Inc. KSF is seeking to determine whether the merger and the process that led to it are adequate, and whether the merger is fair to Kintara shareholders.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240405944592/en/

KTRA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Kintara Therapeutics, Inc. Is Fair to Shareholders

Retrieved on: 
Wednesday, April 3, 2024
Class Action Lawsuit, Professional Services, Legal, Advertising, KTRA, Fraud, Therapy

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kintara shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Kintara Therapeutics, Inc. (NASDAQ: KTRA) and TuHURA Biosciences, Inc. is fair to Kintara shareholders.
  • The investigation concerns whether Kintara and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Kintara shareholders; and (2) disclose all material information necessary for Kintara shareholders to adequately assess and value the merger consideration.
  • On behalf of Kintara shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

Retrieved on: 
Thursday, December 1, 2022
Aravalli Range, Therapy, Progression-free survival, Neoplasm, Assistant professor, Roche, Breast, OTC, Communication, MUC, Gemcitabine, PDAC, Patient, Hematology, Fast Track, CMBC, KTRA, PD-L1, Bladder cancer, Division, Hoffmann-La Roche, Metastatic breast cancer, FDA, ORR, PD-1, Pancreatic cancer, News, Reindeer, PFS, CRISPR, TSX, National Cancer Institute, Rachel Haurwitz, Ministry, OTCQX, Ministry of Food and Drug Safety, Global Innovation through Science and Technology initiative, ONC, Cancer, Fast track (FDA), Vanderbilt University Medical Center, Pharmaceutical industry, Medical imaging, Agency, Oncolytics Biotech, Food, Atezolizumab

VANCOUVER, British Colombia , Dec. 1, 2022 /PRNewswire/ -- USA News Group  -  A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy recipients. The most recent to gain such a designation is pelareorep from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) in combination with atezolizumab, an anti-PD-L1 checkpoint inhibitor from Roche Holding AG (OTCQX: RHHBY) for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). Among the small handful of other companies that recently received this distinction for their platforms have been Aravive, Inc. (NASDAQ: ARAV), Caribou Biosciences, Inc. (NASDAQ: CRBU), and Kintara Therapeutics, Inc. (NASDAQ: KTRA).

Key Points: 
  • The Fast Track process is designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and fill an unmet medical need.
  • Drugs that receive Fast Track designation may be eligible for more frequent communications and meetings with the FDA to discuss the drug's development plan.
  • Drugs with Fast Track designation may also qualify for accelerated and priority review of new drug applications if relevant criteria are met.
  • This represents the second FDA Fast Track designation in Oncolytics' history, with the first being for pelareorep in Metastatic Breast Cancer back in May 2017 .

Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating Up

Retrieved on: 
Thursday, December 1, 2022
Aravalli Range, Therapy, Progression-free survival, Neoplasm, Assistant professor, Roche, Breast, OTC, Communication, MUC, Gemcitabine, PDAC, Patient, Hematology, Fast Track, CMBC, KTRA, PD-L1, Bladder cancer, Division, Hoffmann-La Roche, Metastatic breast cancer, FDA, ORR, PD-1, Pancreatic cancer, News, Reindeer, PFS, CRISPR, TSX, National Cancer Institute, Rachel Haurwitz, Ministry, OTCQX, Ministry of Food and Drug Safety, Global Innovation through Science and Technology initiative, ONC, Cancer, Fast track (FDA), Vanderbilt University Medical Center, Pharmaceutical industry, Medical imaging, Agency, Oncolytics Biotech, Food, Atezolizumab

VANCOUVER, British Colombia, Dec. 1, 2022 /PRNewswire/ -- USA News Group  -  A series of new Fast Track designations have been handed out by the United States Food and Drug Administration (FDA) this week, causing a flurry of activity in the markets for the worthy recipients. The most recent to gain such a designation is pelareorep from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) in combination with atezolizumab, an anti-PD-L1 checkpoint inhibitor from Roche Holding AG (OTCQX: RHHBY) for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). Among the small handful of other companies that recently received this distinction for their platforms have been Aravive, Inc. (NASDAQ: ARAV), Caribou Biosciences, Inc. (NASDAQ: CRBU), and Kintara Therapeutics, Inc. (NASDAQ: KTRA).

Key Points: 
  • The Fast Track process is designed to facilitate the development and expedite the review of investigational drugs to treat serious conditions and fill an unmet medical need.
  • Drugs that receive Fast Track designation may be eligible for more frequent communications and meetings with the FDA to discuss the drug's development plan.
  • Drugs with Fast Track designation may also qualify for accelerated and priority review of new drug applications if relevant criteria are met.
  • This represents the second FDA Fast Track designation in Oncolytics' history, with the first being for pelareorep in Metastatic Breast Cancer back in May 2017 .

Kintara Announces One-for-Fifty Reverse Stock Split

Retrieved on: 
Friday, November 11, 2022
Transfer, Global Coalition Against Pneumonia, Exercise, EST, KTRA, Company, NSCLC, Ovary, Annual report, NCI, Cancer, Board, PDT, Private Securities Litigation Reform Act, National, Therapy, Technology, Research, Central nervous system, SAN, GBM, Neck, Patient, SEC, Glioblastoma, LLC, Nasdaq, Bladder cancer, COVID-19, Head, CUSIP, Marketing, Sumathi Best Television Current Reporting Award, National Cancer Institute, Compliance, Pharmaceutical industry, Security (finance), CMBC

Kintara's common stock will begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market when the market opens on November 14, 2022.

Key Points: 
  • Kintara's common stock will begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market when the market opens on November 14, 2022.
  • As a result of the reverse stock split, every fifty pre-split shares of common stock outstanding and authorized will automatically combine into one new share of common stock without any action on the part of the stockholders.
  • The reverse stock split will also apply to common stock issuable upon the conversion of Kintara's outstanding preferred stock and the exercise of Kintara's outstanding warrants, restricted stock units, and stock options, with adjustments to the conversion prices and exercise prices thereof as required by the terms of those securities.
  • No stockholder approval of the reverse stock split was required under Nevada law, and on October 28, 2022, the Board of Directors of the Company approved and authorized the reverse stock split at a ratio of one-for-fifty (1:50).

Saniona appoints Robert Hoffman to Board of Directors as Chair of the Audit Committee

Retrieved on: 
Thursday, September 16, 2021
St. Bonaventure University, KTRA, Arena, Database, Drug discovery, Weight gain, FASB, IPO, BBA, Heron, Patient, Inactive, Antibe Therapeutics, Pain, CFO, List of life sciences, Nasdaq, Fundraising, Hunger, Degenerative disease, Financial Accounting Standards Board, CPA, Association, Therapy, Tomorrow Could Be the Day Things Change, Strategic planning, Prader–Willi syndrome, ASLN, OMX, Arena Pharmaceuticals, Organization, Accounting, TSX, Disorder, Leadership, Management, Pharmaceutical industry

Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership.

Key Points: 
  • Hoffman is an experienced financial executive and board member with nearly 30 years of experience and achievements in accounting, finance, fund raising, strategic planning, corporate governance, investor relations, and leadership.
  • I see in Saniona a company with a considerable amount of untapped potential.
  • Hoffman also serves as a board member of the Association of Bioscience Financial Officers and FibroBiologics, Inc., a private biotechnology company.
  • As a founder of Day For Change, a not-for-profit that serves underprivileged and abused children in San Diego, Hoffman has served on its board of directors for 20 years.